# Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

> **NCT03767322** · PHASE2 · UNKNOWN · sponsor: **Instituto Nacional de Cardiologia Ignacio Chavez** · enrollment: 558 (estimated)

## Conditions studied

- Contrast-induced Nephropathy
- Contrast-induced Acute Kidney Injury

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Febuxostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03767322
- **Lead sponsor:** Instituto Nacional de Cardiologia Ignacio Chavez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-05
- **Primary completion:** 2019-10
- **Final completion:** 2019-12
- **Target enrollment:** 558 (ESTIMATED)
- **Last updated:** 2018-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03767322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03767322, "Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03767322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*